COMMUNIQUÉS West-GlobeNewswire

Rakovina Therapeutics Announces $1.5 million Non-Brokered Private Placement
23/05/2024
All monetary figures listed in Canadian Dollars. VANCOUVER, British Columbia, May 23, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical [...]
Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
23/05/2024
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients [...]
Pneumagen Presents Positive Phase 2 Influenza Human Challenge Study data on Neumifil, its Broad-Spectrum Antiviral Drug, at the American Thoracic Society (ATS) 2024 Conference
23/05/2024
Neumifil delivers statistically significant reductions in influenza symptomatic infection rate, symptom severity and viral load Strategy to advance clinical development of Neumifil to be based on these positive data and [...]
Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium
23/05/2024
PRESS RELEASE Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium First presentation of a novel mechanism of action for the [...]
Solei Brand Introduces New Cannabis-Infused ‘Warming Deep Tissue Stick’
23/05/2024
Solei’s New Cannabis-Infused Topical Solution is Made for Active Lifestyle Enthusiasts TORONTO, May 23, 2024 (GLOBE NEWSWIRE) -- May 23, 2024 – Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), a leading global lifestyle [...]
TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing
23/05/2024
The Leidos team’s Next-Generation Medical Countermeasures (MCMs) Successfully Formulated with Company’s Proprietary Thin Film Freezing Technology MCM Candidates Demonstrated Chemical and Biological (CB) Neutralizing [...]
Hydreight Technologies through its associated Medical network now offer Tirzepatide to Product Offering which also features GLP-1 Medications (Low-Cost Semaglutide), NAD+ and more
23/05/2024
Tirzepatide, a dual GIP and GLP-1 receptor agonist (GIP/GLP-1 RA), is an antidiabetic medication used for the treatment of type 2 diabetes and for weight loss. The GLP-1 segment is an important class of drugs for [...]
Script Runner launches Canada’s first AI-powered drone delivery service, revolutionizing healthcare access for remote communities
23/05/2024
Thunder Bay test flight bridges healthcare gap; Canadian company prioritizes patient care with last-mile solutions THUNDER BAY, Ontario, May 23, 2024 (GLOBE NEWSWIRE) -- Script Runner, a health technology company that [...]
OneMedNet Reports Greater than Five-Fold Expansion of iRWD™ Network and Platform
23/05/2024
MINNEAPOLIS, May 23, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator of regulatory-grade Real World Data (“RWD”), inclusive of electronic health records [...]
ARCPOINT TO HOST CONFERENCE CALL TO DISCUSS 2024 Q1 FINANCIAL RESULTS
23/05/2024
Greenville, South Carolina, May 23, 2024 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the “ Company ” or “ ARCpoint ”) a leading US-based franchise system providing drug testing, alcohol screening, DNA and direct to [...]
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
23/05/2024
NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, [...]
Disclosure of voting rights at AGM in Vistin Pharma ASA
23/05/2024
Oslo, Norway, 23 May 2024 In relation to the Annual General Meeting in Vistin Pharma ASA (OSE: VISTN), on the 23th of May, the Company's Chair of the Board, Øyvin Brøymer, has received open proxies to represent a total [...]
Disclosure of voting rights for Chair of the Board
23/05/2024
Oslo, 23 May 2024. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of Hans Peter Bøhn, Chair of the Board of Directors. Hans Peter Bøhn is chair of PCI Biotech’s board of [...]
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
23/05/2024
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Atlas Special Opportunities, LLC has converted 8 convertible bonds in Oxurion resulting in a EUR 200,000 capital [...]
Burning Rock Schedules First Quarter of 2024 Earnings Release on May 29, 2024
23/05/2024
GUANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) [...]
ONWARD® Medical Reports Q1 2024 Update and Year-to-Date Highlights
23/05/2024
Nature Medicine published Up-LIFT pivotal trial results Submitted FDA De Novo application for ARC-EX ® System Successfully raised EUR 20M in equity capital EINDHOVEN, the Netherlands, May 23, 2024 (GLOBE NEWSWIRE) -- [...]
EUROAPI strengthens its presence in animal health with a €130-150 million supply contract
23/05/2024
Press Release A 5-year manufacturing contract to support the FOCUS-27 project sales trajectory This contract highlights EUROAPI’s know-how and the reliability of its premium Contract Manufacturing Organization services [...]
EUROAPI renforce sa présence en santé animale avec un contrat de fourniture de 130-150 millions d’euros
23/05/2024
Communiqué de presse Un contrat de fabrication de 5 ans qui soutiendra la trajectoire de ventes du projet FOCUS-27 Ce contrat souligne le savoir-faire d’EUROAPI et la fiabilité des services premium de Contract [...]
Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease
23/05/2024
Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease Additional kidney function analyses strongly support Vivoryon’s shift in strategic focus to [...]

Pages